Active U.S. drug shortages increased to 227 in the second quarter of 2026, marking the third consecutive quarterly increase, according to a new report from the American Society of Health-System Pharmacists.
While shortages remain well below the record 323 reported in the first quarter of 2024, even a single shortage can disrupt care for large numbers of patients.
Here are five updates for health system leaders:
- Forty-eight percent of all new drug shortages in 2026 involve medications made by a single manufacturer, increasing supply chain vulnerability.
- Chemotherapy shortages remain a concern. A new shortage of ifosfamide, caused by manufacturing quality problems at a key supplier, is affecting a drug used in curative regimens for testicular cancer and sarcoma.
- Sixteen percent of active shortages involve controlled substances, creating challenges for patients with chronic pain or ADHD and for health systems performing surgeries and procedures.
- Contrast agent shortages are emerging. Ten percent of new shortages in 2026 involve contrast agents used in CT scans and MRIs.
- Pharmacy teams continue to spend significant time managing shortages, including updating pharmacy automation systems and EHRs, adding to existing workforce pressures.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
